|
|
Vol. 17.03 – 20 February, 2026
|
|
|
|
|
|
|
|
|
Researchers identified beta-1,4-N-acetylgalactosaminyltransferase 4 (B4GALNT4) as a glycogene significantly associated with advanced pathological stages, higher Gleason scores, and poor prognosis in prostate cancer patients. [Advanced Science]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Knockdown of YEATS domain-containing 2 (YEATS2) reduced the metastatic potential of prostate cancer cells both in vivo and in vitro, whereas its overexpression inhibited anoikis and promotes metastasis by upregulating the expression of the DNA damage repair gene RAD50.
[Oncogene]
|
|
|
|
|
|
Investigators explored the anti-cancer effects and mechanisms of action of trichodermamide B in targeting catalase-induced apoptosis in prostate cancer cells.
[Cell Communication and Signaling]
|
|
|
|
|
|
Using integrating bioinformatics analysis and proteomic research, scientists identified 12 differentially expressed proteins in NDGA-treated prostate cancer cells that were associated with EZH2, a histone methyltransferase and a catalytic component of polycomb repressive complex 2.
[Acta Pharmacologica Sinica]
|
|
|
|
|
|
FOSB is downregulated in prostate cancer (PCa), and its high expression in tumors may reduce the risk of PCa progression by influencing characteristic growth-related cancer pathways.
[Cancer Gene Therapy]
|
|
|
|
|
|
Researchers evaluated the impact of miR-340-mediated downregulation of MDM2 on the therapeutic efficacy of p53 gene therapy in p53 non-expressing prostate cancer cells. [Scientific Reports]
|
|
|
|
|
|
|
|
Emerging evidence demonstrates that androgen deprivation therapy (ADT) induces HGF and canonical WNT signaling activation, which further elevates nuclear exporting and ribosomal biogenesis to foster tumor lineage plasticity and promote diverse CRPC phenotypes and double-null prostate cancer development. [Nature Reviews Urology]
|
|
|
|
|
|
|
|
Candel Therapeutics, Inc. announced a $100 million royalty funding agreement with funds managed by RTW Investments, subject to FDA approval of aglatimagene in intermediate- to high-risk, localized prostate cancer.
[Candel Therapeutics, Inc.]
|
|
|
|
|
|
The Prostate Cancer Foundation (PCF) announced $6.3 million in funding for 31 exceptional Young Investigators pursuing groundbreaking discoveries in prostate cancer. [PCF]
|
|
|
|
|
|
|
|
April 17-22, 2026 San Diego, California, United States
|
|
|
|
|
|
|
|
|
|
|
Aarhus University – Aarhus, Denmark
|
|
|
|
|
|
|
Indiana University – Bloomington, Indiana, United States
|
|
|
|
|
|
|
The University of Hong Kong – Hong Kong
|
|
|
|
|
|
|
University of North Carolina at Chapel Hill – Chapel Hill, North Carolina, United States
|
|
|
|
|
|
|
Albert Einstein College of Medicine – Bronx, New York, United States
|
|
|
|
|
|